MDGL
Madrigal Pharmaceuticals Inc.
$602.82
+$0.61(+0.10%)
50
Overall
40
Value
60
Tech
--
Quality
Market Cap
$13.68B
Volume
103.02K
52W Range
$265.00 - $605.00
Target Price
$571.75
Company Overview
| Mkt Cap | $13.68B | Price | $602.82 |
| Volume | 103.02K | Change | +0.10% |
| P/E Ratio | -29.4 | Open | $601.36 |
| Revenue | $180.1M | Prev Close | $602.21 |
| Net Income | $-465.9M | 52W Range | $265.00 - $605.00 |
| Div Yield | N/A | Target | $571.75 |
| Overall | 50 | Value | 40 |
| Quality | -- | Technical | 60 |
No chart data available
About Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest News
These Are the Most and Least Likely Biotech Takeover Targets for 2026
Vince Condarcuri•3 days ago
Analysts Offer Insights on Healthcare Companies: Carlsmed, Inc. (CARL) and Madrigal Pharmaceuticals (MDGL)
Catie Powers•7 days ago
Piper Sandler Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
TipRanks Auto-Generated Intelligence Newsdesk•7 days ago
Piper Sandler Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)
TipRanks Auto-Generated Intelligence Newsdesk•17 days ago
CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
Shalu Saraf•18 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDGL | $602.82 | +0.1% | 103.02K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Madrigal Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW